Phase 2 N=202 Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Survival — 375; 393 Days — p=0.3864
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=31 Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer
Recurrent Breast Cancer · Stage IIIB Breast Cancer · Stage IV Breast Cancer
Primary: Percentage of Patients That Achieved Target Suramin Concentrations in Plasma — 88 percent of patients
Phase 2 N=23 Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection
Infectious Mononucleosis
Primary: Number of Participants With Improvement in Clinical Symptoms and Reductions in Viral Burden From Baseline — 12; 11 participants
Phase 2 N=78 DHA and X-Linked Retinitis Pigmentosa
Retinitis Pigmentosa · X-linked Genetic Diseases
Primary: Rate of LOSS of 31 Hertz Cone Electroretinographic Function — 0.028; 0.022 log microvolts/year — p=0.30
Phase 2 N=26 Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
Hematologic Neoplasms
Primary: Incidence of GVHD — 12 participants
Phase 2 N=111 Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Mantle Cell Lymphoma
Primary: Percentage of Participants Achieving Response — 67.6 percentage of participants with response
Phase 2 N=30 Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
Gastric Cancer · Stomach Cancer
Primary: Clinical Response Rate of an Induction Regimen Consisting of Irinotecan, Cisplatin and Cetuximab — 40 percentage of paticipants
Phase 2 N=17 Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: PSA Response Analyzed Using the PCWG2 Definition — 1; 16 participants
Phase 2 N=265 A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women
Hemostasis · Oral Contraceptive
Primary: Change From Baseline to End of Month 6 in Prothrombin Fragment 1+2 Levels — 169.53; 157.99; 592.29 pmol/L — p=0.958
Phase 2 N=1,146 A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation
Atrial Fibrillation · Thromboembolism
Primary: Adjudicated Incidence of Bleeding Events — 5.5; 12.7; 7.3; 18.3 percent of subjects with outcome event — p=.367
Phase 2 N=2 A Phase I/II Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents
Extravasations of Anthracycline Anti-cancer Agents
Primary: Adverse Events — 2 participants
Phase 2 N=96 Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
Insomnia · Fatigue · Breast Cancer
Primary: Change in Insomnia Severity Index From Baseline to Post-intervention — -4.93; -6.36; 1.04; -1.43 units on a scale
Phase 2 N=10 A Virtual Support Pilot Program for Weight Loss Surgery Patients
Weight · Physical Activity
Primary: BMI — 35.1; 33.9 kg/m2
Phase 2 N=16 Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
Refractory Multiple Myeloma
Primary: Overall Response Rate (ORR) — 4; 7; 5 participants
Phase 2 N=8 Rivastigmine Study in Adolescents With Down Syndrome
Down Syndrome
Primary: Vineland Adaptive Behavior Scales, Second Edition (Survey Interview Form) — -1.7; 2.0 units on a scale